Savolitinib is a targeted therapy primarily indicated for the treatment of specific subtypes of non-small cell lung cancer (NSCLC). Dosing regimens for special populations should be adjusted on an individual basis, covering pregnant women, lactating women, pediatric patients, elderly patients, and those with hepatic or renal impairment. All specific treatment plans must be strictly followed under the guidance of a physician.
Pregnant and Lactating Women
Pregnant Women: Contraindicated
Savolitinib may cause fetal harm. Effective contraceptive measures must be implemented during treatment and for at least 2 weeks after discontinuation of the drug.
Lactating Women
There is no definitive data confirming whether the drug is excreted in human milk. It is recommended to suspend breastfeeding during treatment and for 2 weeks after stopping the medication.
Pediatric and Adolescent Populations
Safety and efficacy data in individuals under 18 years of age are currently lacking. Use should be guided by careful clinical assessment, with off-label use avoided.
Elderly Patients
Patients aged 65 years and above may face an increased risk of adverse reactions (e.g., hepatic dysfunction, edema). Enhanced monitoring and dose adjustment are required.
Patients with Hepatic or Renal Impairment
Hepatic Impairment
No dose adjustment is needed for mild impairment (Child-Pugh Class A). For moderate to severe impairment (Child-Pugh Class B/C), dose reduction or temporary treatment suspension should be considered.
Renal Impairment
No dose adjustment is required for mild to moderate impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min). Data are limited in patients with severe impairment (eGFR < 30 mL/min) or those receiving dialysis, so cautious use is advised.
Drug Interactions
Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin)
Co-administration may increase savolitinib plasma concentrations. Concomitant use should be avoided or dose adjustment implemented.
Strong CYP3A4 Inducers (e.g., rifampicin, phenytoin)
Co-administration may reduce the therapeutic efficacy of savolitinib. Efficacy monitoring is recommended, and consideration should be given to alternative medications.
Precautions
Periodic monitoring of liver function, complete blood count, and cardiac function is required during treatment. In case of severe adverse reactions (e.g., interstitial lung disease, QT interval prolongation), immediate drug discontinuation and medical attention are necessary.
All dosing regimens must be individualized by the treating physician; dose adjustment or treatment discontinuation should not be performed without medical supervision.
Medical Guidance
Savolitinib is a prescription-only medication. Prior to use, genetic testing (e.g., for MET exon14 skipping mutation) must be completed to confirm eligibility for treatment, and therapy should be administered under the supervision of specialist physicians to ensure standardized care.
